A
Apontis Pharma AG
XETRA:APPH
Apontis Pharma AG
XETRA:APPH
Price:
11.25
EUR
2.27%
Market Closed
Market Cap:
95.6m
EUR
Balance Sheet
Balance Sheet Decomposition
Apontis Pharma AG
Apontis Pharma AG
| Current Assets | 23.4m |
| Cash & Short-Term Investments | 14.3m |
| Receivables | 2.7m |
| Other Current Assets | 6.4m |
| Non-Current Assets | 22m |
| Other Non-Current Assets | 22m |
Balance Sheet
Apontis Pharma AG
Apontis Pharma AG
Currency: EUR
Millions
Annual
| Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|
| Assets | ||||||
| Cash & Cash Equivalents |
7
|
8
|
30
|
36
|
27
|
|
| Cash |
7
|
8
|
30
|
36
|
27
|
|
| Total Receivables |
1
|
1
|
3
|
2
|
1
|
|
| Accounts Receivables |
1
|
1
|
3
|
2
|
1
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
4
|
3
|
5
|
3
|
6
|
|
| Other Current Assets |
1
|
0
|
1
|
0
|
1
|
|
| Total Current Assets |
13
|
13
|
38
|
42
|
35
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
1
|
1
|
1
|
1
|
|
| Intangible Assets |
16
|
15
|
15
|
16
|
18
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
1
|
1
|
1
|
1
|
1
|
|
| Other Long-Term Assets |
1
|
1
|
1
|
0
|
4
|
|
| Total Assets |
31
N/A
|
30
-3%
|
54
+82%
|
60
+11%
|
57
-4%
|
|
| Liabilities | ||||||
| Accounts Payable |
3
|
3
|
3
|
5
|
5
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
6
|
|
| Other Current Liabilities |
1
|
1
|
1
|
1
|
0
|
|
| Total Current Liabilities |
4
|
4
|
4
|
6
|
11
|
|
| Long-Term Debt |
13
|
14
|
0
|
0
|
0
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
9
|
8
|
10
|
12
|
16
|
|
| Total Liabilities |
26
N/A
|
26
+1%
|
13
-49%
|
18
+36%
|
27
+49%
|
|
| Equity | ||||||
| Common Stock |
0
|
0
|
9
|
9
|
9
|
|
| Retained Earnings |
2
|
3
|
4
|
33
|
22
|
|
| Additional Paid In Capital |
7
|
7
|
36
|
0
|
0
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
5
N/A
|
3
-25%
|
41
+1 077%
|
42
+2%
|
30
-27%
|
|
| Total Liabilities & Equity |
31
N/A
|
30
-3%
|
54
+82%
|
60
+11%
|
57
-4%
|
|
| Shares Outstanding | ||||||
| Common Shares Outstanding |
9
|
9
|
9
|
8
|
8
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
